We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK Watchdog Slams High Price for Roche’s Kadcyla, Issues Negative Coverage Recommendation
UK Watchdog Slams High Price for Roche’s Kadcyla, Issues Negative Coverage Recommendation
A UK cost-effectiveness agency has recommended not covering Roche’s breast cancer drug Kadcyla because the treatment is too expensive, noting that a discount offered by the Swiss drugmaker wasn’t enough.